Becton, Dickinson and Company's shares have seen considerable buying activity, with firms like Victory Capital Management Inc. and Machina Capital S.A.S. increasing their stakes. However, Los Angeles Capital Management LLC and First Trust Direct Indexing L.P. have reduced their holdings. The company's Q2 earnings outperformed estimates, leading to a rise in share price. Additionally, Barclays raised BDX's price target to $312.00. Despite these positives, the company's lower-than-expected 2024 guidance caused a temporary fall in share price. The firm is viewed as a strong value stock with robust fundamentals for long-term investment. BDX is also lauded for managing healthy balance sheet and strong financials amidst global macroeconomic headwinds. The company's stock has often outperformed its competitors on trading days. The dividend value is set to increase, adding to the investment appeal. However, the CEO's pay structure and BDX's lower annual guidance received some backlash. An announcement revealed Becton Dickinson's intent to ramp up syringe production in the U.S. due to quality concerns with Chinese products. Lastly, the launch of a potentially transformative fingertip blood collection device received FDA clearance.
Becton Dickinson and BDX News Analytics from Mon, 24 Jul 2023 07:00:00 GMT to Fri, 10 May 2024 10:34:08 GMT -
Rating 6
- Innovation 7
- Information 9
- Rumor -2
